Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole April 23, 2024
Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole October 17, 2023
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole December 7, 2022
Pulmocide’s Lead Drug Candidate Opelconazole (PC945) Granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA September 16, 2021
Pulmocide Raises $92 Million in a Series C Financing to Fund Registration Program for PC945 May 27, 2021
